Nanobiotix Shares Fall 5.43% at Close Despite Secured Funding
French biotech company Nanobiotix closed Wednesday's session on November 26 at 17.06 euros, down 5.43% from the previous day. This downturn occurs in a paradoxical context: while the CAC 40 was up 0.88% at 8,096.43 points, the biotechnology company's stock continues its correction after finalizing a strategic financing agreement of $71 million with Healthcare Royalty last Monday, extending its cash horizon until early 2028.
Post-Financing Decline
The decline follows the announcement of the completion of strategic financing with Healthcare Royalty, a classic phenomenon of profit-taking after the stock's recent strong performance. Trading remained moderate with 1.11% of the capital traded during the day. The non-dilutive financing includes an initial payment of $50 million and an additional $21 million expected in a year under certain conditions, extending the visibility of cash flow until early 2028. On a broader perspective, the stock has shown remarkable performance with a gain of 415.4% over the year, significantly outperforming the CAC 40 which gained 11.56% over the same period. Over three months, the stock has surged by 115.4%, particularly driven by advances in the JNJ-1900 program with Johnson & Johnson. However, over the past week, the stock has seen a decline of 7.48%, reflecting a technical consolidation phase after the recent euphoria.
Clinical Progress and Investor Movements
Recent clinical advancements include initial data from a Phase 1 study in esophageal cancer and the completion of the sponsorship transfer of the Phase 3 NANORAY-312 study in head and neck cancer to Johnson & Johnson in most regions. The company expects clinical updates in 2026 from Phase 1 studies in melanoma, lung cancer suitable for re-irradiation, pancreatic cancer, and esophageal cancer. From a shareholder perspective, Goldman Sachs Group reported to the AMF that it had crossed below the 5% voting rights threshold of Nanobiotix on October 29 due to an off-market share sale, indicating a repositioning of institutional investors after the stock's strong appreciation. The company had 20.4 million euros in cash as of September 30, 2025, a position strengthened by the new financing that secures the financial trajectory until 2028.
Technical Perspective
From a technical standpoint, the stock is now trading above its 200-day moving average at 7.74 euros, confirming the strength of the long-term upward trend. The 50-day moving average stands at 17.51 euros, slightly above the current price, suggesting a breathing phase after the recent strong progression. The RSI at 53 points is in a neutral zone, indicating that the stock is neither overbought nor oversold, which leaves room for movement in both directions. The MACD shows a positive histogram at 0.21, with the MACD line at -0.31 above the signal line at -0.52, signaling a potential short-term bullish reversal despite the day's decline. The price is currently fluctuating between a support identified at 13.36 euros and a resistance at 23.75 euros, in a context of high volatility at 27.96% over a month, characteristic of biotechnology stocks in advanced clinical development phase. This range reflects strong investor expectations regarding the clinical catalysts expected in 2026, which will be crucial for the future valuation of the stock.
